20 results on '"Dombernowsky P"'
Search Results
2. Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy.
- Author
-
Sigsgaard T, Herrstedt J, Handberg J, Kjaer M, and Dombernowsky P
- Subjects
- Adult, Aged, Antineoplastic Agents adverse effects, Breast Neoplasms drug therapy, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Logistic Models, Middle Aged, Nausea chemically induced, Statistics, Nonparametric, Vomiting chemically induced, Antiemetics therapeutic use, Glucocorticoids therapeutic use, Isonipecotic Acids therapeutic use, Nausea prevention & control, Ondansetron therapeutic use, Prednisolone therapeutic use, Vomiting prevention & control
- Abstract
Purpose: To compare the antiemetic efficacy and tolerability of ondansetron plus metopimazine with ondansetron plus metopimazine plus prednisolone during nine cycles of moderately emetogenic chemotherapy., Patients and Methods: A total of 221 women with stage I or II breast cancer and no prior chemotherapy who were scheduled to receive adjuvant chemotherapy with intravenous cyclophosphamide, fluorouracil and methotrexate or cyclophosphamide, epirubicin, and fluorouracil given every 3 weeks were included in a double-blind parallel trial. Patients were randomized to 3 days of oral treatment with ondansetron plus metopimazine, or ondansetron plus metopimazine plus prednisolone. Ondansetron was administered as 8 mg bid, metopimazine as 30 mg qid, and prednisolone as 50 mg qd., Results: In all, 216 patients (97.7%) were assessable for efficacy during a total of 1,462 cycles. In cycle 1, complete protection from emetic episodes/nausea day 1, days 2 through 5, and days 1 through 5 was achieved in 84.4%/51.4%, 82.6%/41.3%, and 79.8%/34.9% with ondansetron plus metopimazine and in 84.1%/57.0%, 86.8%/53.8%, and 79.4%/43.0% with ondansetron plus metopimazine plus prednisolone, respectively. In cycle 1, the three-drug combination was superior only in the treatment of nausea on days 2 through 5 (P =.0497). The cumulative emetic protection rate after nine cycles was 0.52 with ondansetron plus metopimazine and 0.75 with ondansetron plus metopimazine plus prednisolone. Side effects were generally few and mild with both treatments. Constipation was the only adverse event significantly more frequent with the three-drug combination (P =.029)., Conclusion: Ondansetron plus metopimazine plus prednisolone is highly effective and superior to ondansetron plus metopimazine during nine cycles of moderately emetogenic chemotherapy.
- Published
- 2001
- Full Text
- View/download PDF
3. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer.
- Author
-
Ryberg M, Nielsen D, Skovsgaard T, Hansen J, Jensen BV, and Dombernowsky P
- Subjects
- Adult, Aged, Antibiotics, Antineoplastic administration & dosage, Drug Administration Schedule, Epirubicin administration & dosage, Heart Failure mortality, Humans, Middle Aged, Neoplasm Metastasis, Retrospective Studies, Risk Factors, Time Factors, Antibiotics, Antineoplastic adverse effects, Breast Neoplasms drug therapy, Epirubicin adverse effects, Heart Failure chemically induced
- Abstract
Purpose: To evaluate the influence of cumulative dose, dose-intensity, single-dose level, and schedule of epirubicin on the risk of developing congestive heart failure (CHF) in patients with advanced breast cancer., Patients and Methods: Four hundred sixty-nine consecutive anthracyline-naive patients with metastatic breast cancer were included. Only patients with cardiac failure according to New York Heart Association (NYHA) function class II or more were recorded as having CHF. For each patient, the following were calculated: the cumulative dose of epirubicin, mean dose-intensity (cumulative dose of epirubicin/duration of treatment), and single-dose level (cumulative dose of epirubicin/number of injections)., Results: Thirty-four patients (7.2%) developed CHF. The cumulative risk of cardiotoxicity was 4% at 900 mg/m2 and increased exponentially to 15% at 1,000 mg/m2. Irradiation against the mediastinum and thoracic spine increased the risk of CHF (P=.025), but dose-intensity, single-dose level, and schedule had no influence on the risk of developing CHF. Age, previous adjuvant irradiation (to the left or right hemithorax), and previous chemotherapy (cyclophosphamide, methotrexate, and fluorouracil [CMF]) were not risk factors. The median time to onset of CHF following the last dose of epirubicin was 57 days (range, 0 to 853). Among patients with CHF, 13 (38.2%) died of cardiac failure. The median survival time for all patients with CHF was 162 days (range, 0 to +1,957). Previous irradiation directly against the heart increased the risk of death due to cardiac failure and decreased the median survival time to 125 days (range, 0 to 336)., Conclusion: The present large retrospective study of 469 patients substantiates previous results concerning the cardiotoxicity of epirubicin. A significantly increasing risk of CHF in patients who receive cumulative doses greater than 950 mg/m2 was established. The future recommended maximum cumulative dose of epirubicin should be 900 mg/m2 in patients with metastatic breast cancer. Previous irradiation against the heart leads to an increased risk of developing CHF with an accelerated course to death, which indicates an additive cardiotoxic effect of irradiation and epirubicin.
- Published
- 1998
- Full Text
- View/download PDF
4. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.
- Author
-
Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M, Fornasiero A, Hoffmann W, Michel J, Hatschek T, Tjabbes T, Chaudri HA, Hornberger U, and Trunet PF
- Subjects
- Administration, Oral, Aged, Antineoplastic Agents adverse effects, Breast Neoplasms mortality, Breast Neoplasms pathology, Disease Progression, Double-Blind Method, Enzyme Inhibitors administration & dosage, Enzyme Inhibitors adverse effects, Female, Humans, Letrozole, Middle Aged, Nitriles adverse effects, Survival Rate, Triazoles adverse effects, Antineoplastic Agents administration & dosage, Aromatase Inhibitors, Breast Neoplasms drug therapy, Megestrol Acetate therapeutic use, Nitriles administration & dosage, Triazoles administration & dosage
- Abstract
Purpose: To compare two doses of letrozole and megestrol acetate (MA) as second-line therapy in postmenopausal women with advanced breast cancer previously treated with antiestrogens., Patients and Methods: Five hundred fifty-one patients with locally advanced, locoregionally recurrent or metastatic breast cancer were randomly assigned to receive letrozole 2.5 mg (n = 174), letrozole 0.5 mg (n = 188), or MA 160 mg (n = 189) once daily in a double-blind, multicenter trial. Data were analyzed for tumor response and safety variables up to 33 months of follow-up evaluation and for survival up to 45 months., Results: Letrozole 2.5 mg produced a significantly higher overall objective response rate (24%) compared with MA (16%; logistic regression, P = .04) or letrozole 0.5 mg (13%; P = .004). Duration of objective response was significantly longer for letrozole 2.5 mg compared with MA (Cox regression, P = .02). Letrozole 2.5 mg was significantly superior to MA and letrozole 0.5 mg in time to treatment failure (P = .04 and P = .002, respectively). For time to progression, letrozole 2.5 mg was superior to letrozole 0.5 mg (P = .02), but not to MA (P = .07). There was a significant dose effect in overall survival in favor of letrozole 2.5 mg (P = .03) compared with letrozole 0.5 mg. Letrozole was significantly better tolerated than MA with respect to serious adverse experiences, discontinuation due to poor tolerability, cardiovascular side effects, and weight gain., Conclusion: The data show letrozole 2.5 mg once daily to be more effective and better tolerated than MA in the treatment of postmenopausal women with advanced breast cancer previously treated with antiestrogens.
- Published
- 1998
- Full Text
- View/download PDF
5. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.
- Author
-
Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, Giaccone G, Schaefer B, Wanders J, and Verweij J
- Subjects
- Aged, Antineoplastic Agents adverse effects, Brain Neoplasms secondary, Camptothecin adverse effects, Camptothecin therapeutic use, Carcinoma, Small Cell secondary, Humans, Remission Induction, Survival Analysis, Topotecan, Antineoplastic Agents therapeutic use, Camptothecin analogs & derivatives, Carcinoma, Small Cell drug therapy, Lung Neoplasms drug therapy
- Abstract
Purpose: To assess activity and toxicity of topotecan in previously treated small-cell lung cancer (SCLC) patients., Patients and Methods: Patients with measurable SCLC, progressive after one first-line regimen, were eligible for the study. Two groups of patients were selected: (1) patients who failed first-line treatment < or = 3 months from chemotherapy discontinuation (refractory group); and (2) patients who responded to first-line treatment and progressed greater than 3 months after chemotherapy discontinuation (sensitive group). Topotecan was administered as a 30-minute daily infusion at a dose of 1.5 mg/m2 for 5 consecutive days, every 3 weeks., Results: One hundred one patients were entered onto the study and 403 courses were administered. Ninety-two patients (47 refractory and 45 sensitive) were eligible and assessable for response. Among refractory patients, there were two partial responses (PRs) and one complete response (CR), for an overall response rate of 6.4% (95% confidence interval [CI], 1.3% to 17.6%), whereas in the sensitive group, there were 11 PRs and six CRs, for an overall response rate of 37.8% (95% CI, 23.8% to 53.5%). Overall median duration of response was 7.6 months. Median survival was 5.4 months; median survival of refractory patients was 4.7 months, whereas that of sensitive patients was 6.9 months (P = .002). Median survival of responding patients was 12.5 months. Toxicity was mainly hematologic. Leukopenia, although short-lived, was universal, with grade III and IV neutropenia occurring in 28% and 46.8% of cycles, respectively. Nonhematological toxicity was mild. Fatigue/malaise was reported in 39.3% of cycles and transient elevation of liver enzymes in 17%., Conclusion: Topotecan has significant activity in SCLC, particularly in patients sensitive to prior chemotherapy, with predictable and manageable toxicity. The incorporation of topotecan in combination chemotherapy regimens for future treatment of SCLC is warranted.
- Published
- 1997
- Full Text
- View/download PDF
6. Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during platinum-based chemotherapy in patients with cancer.
- Author
-
Herrstedt J, Sigsgaard T, Handberg J, Schousboe BM, Hansen M, and Dombernowsky P
- Subjects
- Adult, Aged, Carboplatin adverse effects, Cisplatin adverse effects, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Nausea chemically induced, Neoplasms drug therapy, Severity of Illness Index, Treatment Outcome, Vomiting chemically induced, Antiemetics therapeutic use, Antineoplastic Agents adverse effects, Isonipecotic Acids therapeutic use, Nausea prevention & control, Ondansetron therapeutic use, Platinum Compounds adverse effects, Vomiting prevention & control
- Abstract
Purpose: To investigate the antiemetic effect and tolerability of the 5-hydroxytryptamine3(5-HT3) antagonist ondansetron plus the dopamine D2 antagonist metopimazine versus ondansetron alone in patients receiving platinum-based chemotherapy., Patients and Methods: One hundred eleven chemotherapy-naive patients who were scheduled to receive two consecutive courses of platinum-based chemotherapy were randomized between ondansetron 8 mg intravenously (IV) followed by 8 mg orally twice a day plus metopimazine 35 mg/m2 as a 24-hour continuous infusion followed by 30 mg orally four times a day for 4 days, or ondansetron plus placebo. The study used a double-blind, crossover, placebo-controlled design., Results: Ninety-four patients completed the crossover. Complete response (CR; no emetic episodes) was obtained on day 1 in 77.7% of the patients who received the combination versus 50.0% of those who received ondansetron alone (P = .00002), and in 51.7% versus 31.0% on days 2 to 6 (P = .0009). The overall CR (days 1 to 6) was 48.9% versus 25.3% (P = .0002). Additionally, significantly less nausea was observed with the combination on day 1 (P = .0002), days 2 to 6 (P = .0001), and days 1 to 6 (P = .00004). Patient preference was 63.6% for the combination and 13.6% for ondansetron alone; 22.7% expressed no treatment preference (P < .0001; therapeutic gain 50.0%; 95% confidence interval [CI], 31.6% to 68.4%). Adverse reactions were mild and without significant differences between the two treatments., Conclusion: Metopimazine plus ondansetron was significantly superior to ondansetron alone, concerning all efficacy parameters assessed, in patients who received platinum-based chemotherapy.
- Published
- 1997
- Full Text
- View/download PDF
7. Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years--an analysis of 1,714 consecutive patients.
- Author
-
Lassen U, Osterlind K, Hansen M, Dombernowsky P, Bergman B, and Hansen HH
- Subjects
- Alkaline Phosphatase metabolism, Antineoplastic Agents adverse effects, Antineoplastic Agents therapeutic use, Biomarkers, Tumor analysis, Carcinoma, Small Cell diagnosis, Carcinoma, Small Cell secondary, Carcinoma, Small Cell therapy, Combined Modality Therapy, Disease-Free Survival, Female, Follow-Up Studies, Humans, L-Lactate Dehydrogenase analysis, Lung Neoplasms diagnosis, Lung Neoplasms therapy, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Peripheral Nervous System Diseases etiology, Prognosis, Regression Analysis, Risk Factors, Survival Rate, Survivors statistics & numerical data, Treatment Outcome, Carcinoma, Small Cell mortality, Lung Neoplasms mortality
- Abstract
Purpose: To describe in patients with small-cell lung cancer (SCLC) the characteristics of those who survive for > or = 5 years, to identify long-term prognostic factors, to analyze survival data of 5-year survivors, and to study 10-year survival in patients entered before 1981., Patients and Methods: A total of 1,714 unselected patients with SCLC were treated with combination chemotherapy in nine consecutive clinical trials from 1973 to 1991. All medical records were reviewed and follow-up data obtained to analyze and compare pretreatment and posttreatment characteristics., Results: Sixty patients survived longer than 5 years. Late relapses occurred in 15.0% of 5-year survivors and secondary malignancies in 20.0%. Twenty-six patients are still alive and disease-free 5 to 18 years (median, 9.5 years) from initiation of treatment. Extensive-stage disease, performance status (PS) more than 2, liver and bone marrow metastases, and elevated lactate dehydrogenase (LDH) and alkaline phosphatase levels were all negative prognostic factors. The 5-year survival rate was 3.5% (limited-stage disease, 4.8%; extensive-stage disease, 2.3%), and the 10-year survival rate was 1.8% (limited-stage disease, 2.5%; extensive-stage disease, 1.2%)., Conclusion: Long-term survival can be achieved for both stages of SCLC, but without any change in survival rates over the last decade. Long-term survivors continuously seem to have considerable mortality due to late relapses and secondary malignancies, especially tobacco-related cancers and other tobacco-related diseases.
- Published
- 1995
- Full Text
- View/download PDF
8. Metastatic spinal cord compression secondary to lung cancer.
- Author
-
Bach F, Agerlin N, Sørensen JB, Rasmussen TB, Dombernowsky P, Sørensen PS, and Hansen HH
- Subjects
- Adenocarcinoma secondary, Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung secondary, Carcinoma, Small Cell secondary, Carcinoma, Squamous Cell secondary, Combined Modality Therapy, Denmark epidemiology, Female, Humans, Laminectomy, Life Tables, Male, Middle Aged, Prognosis, Spinal Cord Compression epidemiology, Spinal Neoplasms epidemiology, Treatment Outcome, Lung Neoplasms pathology, Spinal Cord Compression etiology, Spinal Cord Compression therapy, Spinal Neoplasms secondary, Spinal Neoplasms therapy
- Abstract
Purpose: Metastatic spinal cord compression (MSCC) is a disabling complication to cancer, the optimal treatment for which is not settled. An analysis was performed for all patients with MSCC secondary to lung cancer in East Denmark from 1979 to 1988., Patients and Methods: The total series included 102 cases with small-cell carcinoma (SCLC; 40%), adenocarcinoma (ACL; 26%), squamous cell carcinoma (SQLC; 18%) and large-cell carcinoma (LCC; 9%). Symptoms, clinical presentations, and therapeutic results are described., Results: The outcome of treatment depended fundamentally on the patient's neurologic condition at the time of the diagnosis. All patients with SCLC who were able to walk at the time of MSCC remained ambulatory, whereas 15% of the nonambulatory SCLC patients regained walking ability. In non-SCLC, 95% of patients continued to be able to walk, whereas 22% regained the ability to walk. No major differences in the immediate outcome of treatment between the various histologic types of lung cancer and the different treatment modalities were observed; however, 82% of the patients with non-SCLC benefited from treatment with laminectomy followed by radiotherapy (RT) compared with either laminectomy (47%) or RT (39%) alone (P = .03, chi 2 test). The group of patients who were treated with laminectomy followed by RT had a better survival (median value, 3.5; range, 0 to 132 months) than patients who were treated with either laminectomy (median value, 1.5; range, 0 to 32 months) or RT (median value, 1; range, 0 to 59 months) alone (P = .03, log-rank test). No significant difference was observed in survival between the various histologic types of lung cancer (P = .18, log-rank test)., Conclusion: Despite a short survival, early diagnosis and immediate treatment is crucial because it may preserve the gait function in 97% of lung cancer patients who develop malignant spinal cord compression.
- Published
- 1992
- Full Text
- View/download PDF
9. Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 11q23 after therapy with 4-epi-doxorubicin and cisplatin or cyclophosphamide for breast cancer.
- Author
-
Pedersen-Bjergaard J, Sigsgaard TC, Nielsen D, Gjedde SB, Philip P, Hansen M, Larsen SO, Rørth M, Mouridsen H, and Dombernowsky P
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cisplatin adverse effects, Cyclophosphamide adverse effects, Doxorubicin adverse effects, Drug Synergism, Female, Humans, Leukemia, Monocytic, Acute genetics, Leukemia, Myelomonocytic, Acute genetics, Prospective Studies, Antineoplastic Combined Chemotherapy Protocols adverse effects, Breast Neoplasms drug therapy, Chromosomes, Human, Pair 11 drug effects, Leukemia, Monocytic, Acute chemically induced, Leukemia, Myelomonocytic, Acute chemically induced, Translocation, Genetic drug effects
- Abstract
Purpose: To report five cases of acute monocytic or myelomonocytic leukemia after chemotherapy with 4-epidoxorubicin for breast cancer and to evaluate the risk of leukemia after the use of this drug., Patients and Methods: One hundred fifty-seven patients with advanced breast cancer were randomized to either 4-epi-doxorubicin plus cisplatin or 4-epi-doxorubicin alone. An additional 203 patients were treated prospectively with 4-epi-doxorubicin alone. All were observed closely for leukemic complications., Results: Three patients from the randomized study developed leukemia; all were in the subgroup of 74 patients who received 4-epi-doxorubicin plus cisplatin, whereas no leukemia was observed among the remaining 83 patients in the randomized study or among the additional 203 patients who were treated prospectively with 4-epi-doxorubicin alone (P = .023, log-rank test). In the subgroup of 74 patients who were treated with 4-epi-doxorubicin plus cisplatin, the cumulative risk of leukemia was 16.0% +/- 9.9% (mean +/- SE) 33 months after the start of therapy; the relative risk was 668 (95% confidence interval [Cl], 138 to 1,953). Two other cases of acute monocytic and myelomonocytic leukemia were observed after 4-epi-doxorubicin plus alkylating agents were administered for breast cancer. Three of five cases of leukemia presented balanced translocations to chromosome band 11q23 and two, loss of a whole chromosome no. 7 or its long arm., Conclusions: 4-epi-doxorubicin is leukemogenic, and the leukemias are often acute monocytic or myelomonocytic with balanced chromosome translocations to band 11q23, such as in the leukemias after therapy with the epipodophyllotoxins. Furthermore, our results suggest a synergistic effect in leukemogenesis between 4-epi-doxorubicin targeting DNA-topoisomerase II and directly genotoxic drugs such as cisplatin or alkylating agents.
- Published
- 1992
- Full Text
- View/download PDF
10. Teniposide and etoposide in previously untreated small-cell lung cancer: a randomized study.
- Author
-
Bork E, Ersbøll J, Dombernowsky P, Bergman B, Hansen M, and Hansen HH
- Subjects
- Aged, Aged, 80 and over, Drug Administration Schedule, Etoposide adverse effects, Female, Humans, Infusions, Intravenous, Male, Prospective Studies, Teniposide adverse effects, Carcinoma, Small Cell drug therapy, Etoposide therapeutic use, Lung Neoplasms drug therapy, Teniposide therapeutic use
- Abstract
A randomized study comparing teniposide (VM-26) and etoposide (VP-16) was performed to investigate whether there are any differences in the activity and toxicity of these two analogs in small-cell lung cancer (SCLC). Only previously untreated patients with SCLC were included; 46 and 48 patients receiving VP-16 and VM-26, respectively, are assessable for response. There were no differences between the two groups with respect to extent of disease, median age, and performance status (PS). The initial doses were for both compounds 70 mg/m2 intravenously (IV) daily for 5 days every 3 weeks. After inclusion of 25 patients in the study, the doses were increased to 80 mg/m2 for VM-26 and 90 mg/m2 for VP-16 because of differences in toxicity. VM-26 caused more hematologic toxicity than VP-16 throughout the study. The overall responses (complete response [CR] plus partial response [PR]) were 65% for VP-16 and 71% for VM-26, with CR occurring in 24% and 23%, respectively, for the two compounds. Median survival was 8.5 months for VP-16-treated patients versus 11.3 months for VM-26-treated patients (P = .58). It is concluded that both VP-16 and VM-26 are highly active single agents in SCLC.
- Published
- 1991
- Full Text
- View/download PDF
11. Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer.
- Author
-
Nielsen D, Jensen JB, Dombernowsky P, Munck O, Fogh J, Brynjolf I, Havsteen H, and Hansen M
- Subjects
- Adult, Aged, Breast Neoplasms physiopathology, Female, Humans, Middle Aged, Stroke Volume drug effects, Breast Neoplasms drug therapy, Cardiovascular Diseases chemically induced, Epirubicin adverse effects
- Abstract
The cardiotoxicity of epirubicin (EPI) was evaluated clinically, radiologically, with ECG, and with multiple ECG-gated radionuclide determination of the left ventricular ejection fraction (LVEF) during rest in 135 patients with advanced breast cancer. The EPI doses were 60 mg/m2 on days 1 and 8 every 4 weeks or 45 mg/m2 plus vindesine 3 mg/m2 on the same schedule. The median cumulative dose of EPI was 500 mg/m2 (range, 47 to 1,563). Eight of the 135 patients developed congestive heart failure (CHF). Of 67 patients treated with EPI less than 500 mg/m2, none developed CHF. Among 48 patients treated with doses between 500 and 1,000 mg/m2, one had CHF (2%; 95% confidence limits, 0.1 to 11.1). Among 20 patients who received EPI from 1,000 to 1,563 mg/m2, seven developed CHF (35%; 95% confidence limits, 15.4 to 59.2). Four patients died due to cardiotoxicity. The risk of EPI cardiotoxicity at the present schedule is considerable at doses above 1,000 mg/m2. At doses between 500 and 1,000 mg/m2 the risk of CHF decreases, and at doses below 500 mg/m2, it is negligible. For all patients, the prevalence of CHF was 6% and the sensitivity of LVEF high (95%), mainly due to the low incidence of CHF. Among the 20 patients who received EPI at more than 1,000 mg/m2, the prevalence of CHF was 35% and the sensitivity only 64%. The specificity was maximally 62%. Our results suggest that LVEF is of no value as a predictor for CHF.
- Published
- 1990
- Full Text
- View/download PDF
12. Long-term disease-free survival in small-cell carcinoma of the lung: a study of clinical determinants.
- Author
-
Osterlind K, Hansen HH, Hansen M, Dombernowsky P, and Andersen PK
- Subjects
- Adolescent, Adult, Age Factors, Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Small Cell pathology, Carcinoma, Small Cell therapy, Child, Child, Preschool, Clinical Trials as Topic, Combined Modality Therapy, Female, Humans, Infant, Lung Neoplasms pathology, Lung Neoplasms therapy, Male, Middle Aged, Neoplasm Metastasis, Probability, Prognosis, Regression Analysis, Sex Factors, Time Factors, Uric Acid blood, Carcinoma, Small Cell mortality, Lung Neoplasms mortality
- Abstract
The influence of treatment and of pretreatment patient characteristics on the probability of long-term disease-free survival in small-cell lung cancer (SCLC) was investigated in a consecutive series of 874 patients. The patients were included in six controlled treatment trials from 1973 to 1981, using different combinations of chemotherapy with or without irradiation. All patients underwent pretreatment staging, including bronchoscopy, peritoneoscopy with liver biopsy, and bone marrow examination. The same procedures were repeated in patients without overt signs of disease 18 months from initiation of treatment, and patients without evidence of SCLC were regarded as long-term survivors. Seventy-two patients were disease-free at restaging, corresponding to 13% of 443 patients with limited-stage disease and 3% of 431 patients with extensive-stage disease. The possible relationship between different pretreatment variables and the probability of 18 months' disease-free survival was investigated by multiple regression analysis. Disease extent was the most important determinant of long-term survival. Being a woman was a positive factor and hypouricemia had negative influence on the long-term results, while features such as performance status and serum lactate dehydrogenase (LDH) did not have significant influence in the regression model. Differences between the efficacy of the applied treatment regimens were less in limited disease than they were in extensive disease, in which six-agent regimens of alternating chemotherapy was significantly better than treatment with three- or four-agent regimens. Accordingly, disease extent seems to be the most pivotal determinant of long-term survival in SCLC, but influence of the patient's sex and serum urate concentration should also be considered.
- Published
- 1986
- Full Text
- View/download PDF
13. Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer.
- Author
-
Brincker H, Rose C, Rank F, Mouridsen HT, Jakobsen A, Dombernowsky P, Panduro J, and Andersen KW
- Subjects
- Adult, Amenorrhea epidemiology, Breast Neoplasms analysis, Breast Neoplasms mortality, Clinical Trials as Topic, Female, Fluorouracil therapeutic use, Follow-Up Studies, Humans, Lymphatic Metastasis, Menopause, Menstrual Cycle, Methotrexate therapeutic use, Middle Aged, Neoplasm Recurrence, Local epidemiology, Prognosis, Prospective Studies, Random Allocation, Receptors, Estrogen analysis, Time Factors, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms drug therapy, Cyclophosphamide therapeutic use, Ovariectomy
- Abstract
This prospective randomized trial, conducted by the Danish Breast Cancer Cooperative Group, is the largest study, so far, of adjuvant chemotherapy in premenopausal breast cancer. The trial is unique in that it is nationwide and based on a nonselected population of patients, and is the only adjuvant trial studying the effect of cyclophosphamide monotherapy. After total mastectomy with axillary node sampling, followed by local radiotherapy, 1,032 pre- and perimenopausal women with operable breast cancer were randomized to observation alone, or to adjuvant chemotherapy for 1 year with either cyclophosphamide monotherapy or with a combination of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF). As of January 1987, median follow-up was 68 months. From early on both cyclophosphamide alone and CMF were found to improve recurrence-free survival (RFS) significantly and to a similar degree (P = .0001). However, an overall survival advantage did not become evident until 5 years after the start of treatment. So far, this advantage appears to be more pronounced in CMF (P = .0065) than in cyclophosphamide-only patients (P = .08). Thus, the study confirms the findings of the National Surgical Adjuvant Breast Project (NSABP) and Milan trials that adjuvant chemotherapy prolongs the survival of premenopausal women with early breast cancer. A retrospective analysis revealed that, in contrast with CMF, cyclophosphamide alone did not improve RFS significantly in subsets of patients without amenorrhea, with estrogen-receptor (ER) negative tumors, and with tumors of low histological differentiation. Assuming that cyclophosphamide alone is a less tumoricidal treatment than CMF, these findings suggest that the effect of adjuvant cytotoxic chemotherapy is mediated partly through chemical castration, and partly through a purely cytotoxic effect.
- Published
- 1987
- Full Text
- View/download PDF
14. Teniposide (VM-26), an overlooked highly active agent in small-cell lung cancer. Results of a phase II trial in untreated patients.
- Author
-
Bork E, Hansen M, Dombernowsky P, Hansen SW, Pedersen AG, and Hansen HH
- Subjects
- Aged, Drug Administration Schedule, Drug Evaluation, Humans, Middle Aged, Neoplasm Metastasis, Teniposide administration & dosage, Teniposide therapeutic use, Carcinoma, Small Cell drug therapy, Lung Neoplasms drug therapy, Podophyllotoxin analogs & derivatives, Teniposide toxicity
- Abstract
Teniposide, VM-26 (Vumon), was administered in a dose of 60 mg/m2 on days 1 to 5 every third week to 36 patients with histologically confirmed small-cell lung cancer. None had previously received chemotherapy or radiotherapy. The median age was 73 years (range, 52 to 79). Thirty-three patients were evaluable; 21 of these had local disease. Five patients had bone marrow metastases, four had liver involvement, and one CNS metastases. All patients had a performance status less than or equal to 2 before the start of treatment. Thirty patients obtained a response (90%), ten of whom had a complete remission (30%). The median duration of remission was 8+ months (range, 1.1 to 17+ months), whereas the median survival was 8.7 months (range, 1.9 to 20 months). Toxicity was primarily hematologic, with leukopenia the only dose-limiting effect. Besides alopecia, all other side effects were minimal including nausea and vomiting. We find these results provocative in regard to the response rate and the duration of response obtained as well as in reference to the dismal results that prior investigations in previously treated patients have shown. These data may indicate the need for reconsideration of the usual strategy for performing phase II trials.
- Published
- 1986
- Full Text
- View/download PDF
15. Castration induced by cytotoxic chemotherapy.
- Author
-
Brincker H, Mouridsen HT, Andersen KW, Rose C, and Dombernowsky P
- Subjects
- Adult, Clinical Trials as Topic, Combined Modality Therapy, Cyclophosphamide administration & dosage, Female, Fluorouracil administration & dosage, Humans, Methotrexate administration & dosage, Middle Aged, Random Allocation, Amenorrhea chemically induced, Antineoplastic Combined Chemotherapy Protocols adverse effects, Breast Neoplasms therapy, Cyclophosphamide adverse effects
- Published
- 1989
- Full Text
- View/download PDF
16. The superiority of combination chemotherapy including etoposide based on in vivo cell cycle analysis in the treatment of extensive small-cell lung cancer: a randomized trial of 288 consecutive patients.
- Author
-
Hirsch FR, Hansen HH, Hansen M, Osterlind K, Vindeløv LL, Dombernowsky P, and Sørensson S
- Subjects
- Antineoplastic Combined Chemotherapy Protocols adverse effects, Autopsy, Carcinoma, Small Cell mortality, Carcinoma, Small Cell pathology, Clinical Trials as Topic, Drug Administration Schedule, Etoposide administration & dosage, Female, Hematologic Diseases chemically induced, Humans, Lung Neoplasms mortality, Lung Neoplasms pathology, Male, Methotrexate administration & dosage, Middle Aged, Random Allocation, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Small Cell drug therapy, Lung Neoplasms drug therapy
- Abstract
Two hundred and eighty-eight patients with extensive small-cell carcinoma of the lung (SCCL) were entered into a three-arm prospective randomized trial. The purpose was both to compare etoposide with methotrexate (MTX) in a combination chemotherapy regimen otherwise consisting of vincristine (VCR), lomustine (CCNU), and cyclophosphamide (CTX) and to evaluate a treatment design based on cell kinetic observations suggesting enhanced sensitivity to etoposide three to six days after administration of VCR, CCNU, and CTX. In all three treatment arms, VCR, CCNU, and CTX were administered on day 1 of a 28-day cycle. In arm A, MTX was administered on days 14 and 17, while in arm B, MTX was replaced by etoposide administered on days 14 through 17. In arm C, MTX was also replaced by etoposide, but administered on days 3 through 6. Overall survival was significantly longer for patients treated with "early" etoposide (arm C; median, 33 weeks) as compared with arm A (MTX; median, 23 weeks) (P less than .05), but not statistically different from "late" etoposide administration (arm B; median, 27 weeks). However, for patients with initial favorable performance status (0 + 1), a significantly longer survival was obtained for those treated with early etoposide (arm C. median, 51 weeks) as compared with patients in arm A (median, 32 weeks) and arm B (median, 36 weeks) (P less than .05). Two-year survival was obtained in six patients (7%) in arm C compared with three patients (3%) in arm B and none in arm A. The study confirmed that etoposide is an active drug in the treatment of SCCL and when combined with CTX, CCNU, and VCR, the cell kinetic approach of an early administration yields the best results.
- Published
- 1987
- Full Text
- View/download PDF
17. Randomized phase II trial of carminomycin versus 4'-epidoxorubicin in advanced breast cancer.
- Author
-
Rozencweig M, ten Bokkel Huinink W, Cavalli F, Bruntsch U, Dombernowsky P, Høst H, Bramwell V, Renard G, Van Glabbeke M, and Decoster G
- Subjects
- Adult, Aged, Alopecia chemically induced, Breast Neoplasms mortality, Breast Neoplasms pathology, Carubicin adverse effects, Doxorubicin adverse effects, Drug Evaluation, Epirubicin, Female, Follow-Up Studies, Heart Diseases chemically induced, Humans, Leukopenia chemically induced, Middle Aged, Nausea chemically induced, Neoplasm Metastasis, Random Allocation, Vomiting chemically induced, Breast Neoplasms drug therapy, Carubicin administration & dosage, Daunorubicin analogs & derivatives, Doxorubicin administration & dosage
- Abstract
Sixty-three evaluable patients with advanced breast cancer were randomly allocated to receive three-week intravenous courses of carminomycin (18 mg/m2) or 4'-epidoxorubicin (90 mg/m2). The former yielded one (3%) partial response for nine weeks among 29 patients whereas, in the other arm, nine (27%) of 34 patients achieved partial response for a median of 28 weeks (range, nine to 36 weeks; p less than 0.02). The major toxic effect of these anthracyclines was leukopenia with median white blood cell nadirs of 1,600/microL (range, 300-4,000/microL) versus 1,800/microL (range, 500-4,300/microL), respectively. Acute nonhematologic toxic effects were qualitatively similar but carminomycin produced significantly less gastrointestinal intolerance and alopecia. Patients whose disease failed to respond to first-line anthracycline received doxorubicin (60 mg/m2) every three weeks. Four partial responses were obtained among 19 patients previously treated with carminomycin. Following 4'-epidoxorubicin therapy, one of 12 evaluable patients also attained partial response. Survival curves were not affected by the initial treatment option. Carminomycin has marginal activity against breast cancer whereas 4'-epidoxorubicin deserves further evaluation of its therapeutic index relative to doxorubicin. The design used in this trial appears attractive for prompt phase II evaluation of anthracycline analogs.
- Published
- 1984
- Full Text
- View/download PDF
18. Mortality and morbidity in long-term surviving patients treated with chemotherapy with or without irradiation for small-cell lung cancer.
- Author
-
Osterlind K, Hansen HH, Hansen M, and Dombernowsky P
- Subjects
- Aged, Carcinoma, Small Cell drug therapy, Carcinoma, Small Cell radiotherapy, Female, Humans, Leukemia secondary, Lung Neoplasms drug therapy, Lung Neoplasms radiotherapy, Male, Middle Aged, Neoplasms, Multiple Primary, Regression Analysis, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Small Cell mortality, Lung Neoplasms mortality
- Abstract
Mortality and morbidity was investigated in a consecutive series of 72 patients with small-cell lung cancer (SCLC) who were found to be disease-free at restaging after 18 months of treatment. These patients were all the long-term survivors among 874 patients included in one of six trials between 1973 and 1981. All studies used combination chemotherapy with or without irradiation. Follow-up of the patients varied between 4 and 11 years. The estimated 5-year survival rate subsequent to discontinuation of therapy was 0.24, corresponding to a death rate of 0.25 per year or ten times greater than the expected mortality for persons of the same age group. This high mortality was primarily related to recurrent SCLC, the estimated cumulative risk of relapse reaching 46% at the time of the latest recurrence 5 years from diagnosis. The risk of relapse was generally independent of the pretreatment disease stage although it was reduced in patients with resectable disease and was greater in those with pretreatment liver or bone marrow metastases. Equal risks of relapse were related to the use of regimens with and without radiotherapy. The cumulative risk of relapse in patients surviving 3 years from initiation of the treatment was less than 15% and accordingly, 3 years of follow-up seems sufficient for comparison of long-term results obtained in different trials. The second factor resulting in death or disease was second cancer, for which the cumulated risk increased to 32%, the latest occurring 5.4 years from the diagnosis of SCLC. Five of these cases were non-small-cell lung cancers and three were secondary leukemias. The estimated mortality related to non-neoplastic conditions was just significantly greater than expected. In spite of the increased mortality in this series, 38 of 54 2-year disease-free survivors and 20 of 22 5-year survivors resumed a lifestyle similar to that before diagnosis of SCLC.
- Published
- 1986
- Full Text
- View/download PDF
19. Chemotherapy for adenocarcinoma of the lung (WHO III): A randomized study of vindesine versus lomustine, cyclophosphamide, and methotrexate versus all four drugs.
- Author
-
Sørensen JB, Hansen HH, Dombernowsky P, Bork E, Malmberg R, Aabo K, Bødker B, and Hansen M
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Bone Marrow Diseases chemically induced, Cyclophosphamide administration & dosage, Cyclophosphamide adverse effects, Drug Evaluation, Female, Humans, Lomustine administration & dosage, Lomustine adverse effects, Male, Methotrexate administration & dosage, Methotrexate adverse effects, Middle Aged, Peripheral Nervous System Diseases chemically induced, Random Allocation, Vindesine adverse effects, Adenocarcinoma drug therapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Lung Neoplasms drug therapy, Vindesine therapeutic use
- Abstract
Two hundred seventy-nine patients with previously untreated nonresectable adenocarcinoma of the lung (ACL) entered a prospective randomized trial, comparing vindesine (VDS) to a combination of lomustine (CCNU), cyclophosphamide (CTX), and methotrexate (MTX), and to a regimen including all four drugs. Response assessment was possible in 218 patients, while 259 were evaluable for survival. Response rates were similar (22%, 23%, and 27%, respectively) as were median durations of response (15 weeks overall) and survival (29 weeks overall). Patients with dose-limiting toxicity had significantly higher response rate and longer survival than patients without toxicity. The major toxicity was peripheral neuropathy with VDS treatment and myelosuppression with the other two regimens. The VDS single-agent activity in ACL was confirmed, but addition of VDS to the three-drug regimen did not increase activity. Future studies of VDS in combination with other active agents, and comparison to a matched control group on supportive care, are indicated.
- Published
- 1987
- Full Text
- View/download PDF
20. Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis.
- Author
-
Sørensen JB, Hansen HH, Hansen M, and Dombernowsky P
- Subjects
- Adenocarcinoma drug therapy, Adenocarcinoma mortality, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Brain Neoplasms mortality, Clinical Trials as Topic, Female, Humans, Male, Middle Aged, Prognosis, Random Allocation, Risk Factors, Adenocarcinoma secondary, Brain Neoplasms secondary, Lung Neoplasms drug therapy
- Abstract
A consecutive group of 259 patients with inoperable adenocarcinoma of the lung (ACL) were observed to define risk groups for and frequency of brain metastases together with prognosis. All patients received chemotherapy in a three-armed randomized trial. Brain metastases were diagnosed in 25 patients before protocol entry and in 37 during treatment. Brain autopsy was performed in 87 patients and was positive in 38 (44%). Eleven of these (29%) were not diagnosed clinically. Patients younger than 60 years had a somewhat higher overall frequency of brain metastases than older patients. Patients with initial performance status above 60% and patients responding to chemotherapy had higher risk for developing brain metastasis during treatment than other patients, probably because of the increasing cumulated risk for this complication with prolonged survival. Median survival after onset of brain metastases was 73 days and survival was significantly shorter for these patients than for patients without this complication at days 0, 90, 180, and 365 after protocol entry. Thus, brain metastases is a frequent complication in ACL and the frequency increases with prolonged survival. Survival after development of brain metastases is short and it is questionable whether the inclusion of this subgroup of ACL patients into experimental cytostatic treatments is justified.
- Published
- 1988
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.